MiR-4728 affects the efficacy of targeted therapy for HER2-amplified breast cancer by targeting ESR1 and modulating ERα-mediated NOXA transcription to slow apoptosis following treatment with the HER2 inhibitor lapatinib [106]. This evidence concerns the gene ERBB2 and breast carcinoma.